An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
An international research team has developed a new strategy that can predict the potential clinical implications of new therapeutic compounds based on simple cellular responses. This discovery was partly led by scientists affiliated with Université de Montréal (UdeM), and represents a major step forward in developing more effective drugs with fewer side effects, much faster than before. The researchers conducted their work at Centre de Recherche de l’Hôpital Ste-Justine and published their findings in the prestigious journal Nature Communications.
Developing new drugs is a long, complex and costly process. It starts with identifying the molecule or “ligand” (such as a drug, hormone or neurotransmitter) that can activate or block the target or “receptor” involved in a disease. Compound identification and validation is one of the most important steps in ensuring that a new drug provides an effective clinical response with the fewest possible side effects.
“Most new drugs tested on human subjects fail in clinical trials because the therapeutic response is insufficient. Developing a strategy that infers potential clinical responses early in the drug discovery process would significantly improve drug candidate selection,” said Besma Benredjem, the study’s co-lead author and a doctoral student in pharmacology at UdeM.
Finding the needle in a haystack
“Our main goal was finding a way to categorize a large number of drug candidates based on similarities in their effectiveness in triggering a multiplicity of cellular responses that help identify the therapeutic action of new compounds,” said Professor Graciela Piñeyro, co-senior author of the study and a researcher at CHU Sainte-Justine. To accomplish this, she worked with Dr. Olivier Lichtarge of Baylor College of Medicine, who uses advanced bioinformatic analysis to compare and group ligands according to fairly comprehensive signalling profiles.
Drugs produce desired or undesired clinical actions by changing basic signals within cells. By grouping drugs with known clinical actions and new ligands, we can infer the clinical actions of new compounds by comparing the similarities and differences in their signals with known drugs to promote desired clinical responses and avoid side effects.
This method of analysis was developed by using opioid analgesics as prototypes. This made it possible for the team to associate simple cellular signals produced by opioids such as oxycodone, morphine and fentanyl with the frequency with which respiratory depression and other undesirable side effects of these drugs were reported to the Food and Drug Administration’s pharmacovigilance program. At the height of the opioid epidemic, when the risk of death by respiratory depression is at its highest, the team believes this new analytical strategy could lead to the development of safer opioids.
“Thanks to our findings, we can now classify a large number of compounds while taking a multitude of cellular signals into account. The wealth of comparisons this provides increases this classification’s predictive value for clinical responses,” said Professor Michel Bouvier, the study’s co-senior author and a principal investigator of molecular pharmacology and Chief Executive Officer of UdeM’s Institute for Research in Immunology and Cancer. “We think we can help patients by speeding up the drug discovery process so clinical trials can start earlier.”
“Our next goal is to use a similar approach to test cannabis products that may produce harmful neuropsychiatric actions among young people, and identify which cannabis extracts are most effective at treating chronic pain,” added Besma Benredjem.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- Protecting IP and Rapid Vaccine Development Go Hand in Handon November 27, 2020 at 8:01 pm
It has been an awful year as COVID-19 has spread across the globe infecting and killing millions of people. One of the few bright spots in 2020 has been the ...
- Biogen makes risky bet on trial depression drugon November 27, 2020 at 2:58 pm
The $1.5 billion deal with Sage Therapeutics will try to salvage an oral treatment that had a disappointing clinical trial ...
- Sage Gets $3 Billion Endorsement of Its Depression Drugs From Biogenon November 27, 2020 at 12:25 pm
Shaken by a government advisory panel’s poor review of its experimental treatment for Alzheimer’s disease, Biogen announced a team-up Friday with Sage Therapeutics. Biogen has committed up to $3.1 ...
- Sage to Get $1.53 Billion From Biogen for Depression Drug Developmenton November 27, 2020 at 9:42 am
The companies will develop Sage’s zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders.
- With COVID-19 Vaccine Development Complete, Pharma Companies Look To Next Challengeon November 27, 2020 at 7:00 am
The companies facing unprecedented efforts to deliver a COVID-19 vaccine now face new difficulties in production and distribution.
- Antifungal Drugs Market Growing Rapidly with Trends, Development, Investment Opportunities, Size, Share, Revenue, Demand and Forecast to 2025on November 27, 2020 at 3:00 am
Nov (The Expresswire) -- Global"Antifungal Drugs Market"(2020-2026) status and position of worldwide and key regions, with perspectives ...
- Platinum based Cancer Drug Market Historical Analysis, Development Status, Business Growth and Regional Forecast To 2025on November 26, 2020 at 5:30 am
The Platinum based Cancer Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape ...
- Schrödinger in drug development agreement with Bristol Myers worth up to $2.7 billion in milestone and royalty paymentson November 23, 2020 at 4:01 am
Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in ...
- Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibbon November 23, 2020 at 3:30 am
Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collaboration with Bristol Myers Squibb Company ...
- Clearing the course for glycans in development of flu drugson November 20, 2020 at 7:39 am
There is no hole-in-one drug treatment when it comes to the flu, but that doesn't stop scientists from trying to sink one. Especially since as many as one in five Americans gets the flu. The reported ...
via Bing News